이 페이지는 자동 번역되었으며 번역의 정확성을 보장하지 않습니다. 참조하십시오 영문판 원본 텍스트의 경우.

Sober Network IPT for Perinatal Women With Comorbid Substance Use and Depression

2016년 3월 29일 업데이트: Caron Zlotnick, Women and Infants Hospital of Rhode Island
This study will evaluate the effectiveness of Sober Network Interpersonal Psychotherapy (IPT) in treating women with depression and comorbid substance abuse.

연구 개요

상세 설명

Substance use disorder (SUD) and major depressive disorder (MDD) are significant and interconnected public health problems facing women, especially perinatal women. Perinatal women with co-occurring SUD-MDD are of public health concern because they face numerous neonatal and obstetrical risks in addition to the emotional distress, impairment, and adverse health effects associated with these disorders. MDD is common in women with SUD, often does not remit with SUD treatment, increases the risk of poor SUD treatment outcome, and should be treated. Despite the serious morbidity associated with both SUD and MDD in perinatal women and despite the consensus among perinatal researchers that there is a need for population-specific treatments that address the unique set of challenges associated with this period of a women's life, virtually no interventions have been developed or tested to address the specific needs of perinatal women with comorbid substance use and depression. Furthermore, many tests of existing treatments for SUD-MDD in any population have demonstrated limited efficacy for at least one of the two disorders.

The investigators propose to pilot test a novel 18-20 week group treatment for SUD-MDD, Sober Network Interpersonal Psychotherapy(IPT), which focuses on network support strategies for SUD (i.e., enhancement of active sober support) within a broader Interpersonal Psychotherapy (IPT) framework. IPT is the treatment of choice for MDD in perinatal populations. Sober network support is theoretically consistent with IPT and has been identified as an empirically supported mechanism of change of many efficacious SUD treatments. Interpersonal difficulties not only affect MDD, but are also strong predictors of SUD relapse in women. A social/interpersonal approach to SUD-MDD may be highly efficacious for and relevant to the needs of perinatal women because specific interpersonal challenges become more salient during the perinatal period. Pilot work (supported by Dr. Johnson's NIDA K23), has shown an IPT-based treatment to be feasible, acceptable, and efficacious for MDD among women prisoners with SUD-MDD, another vulnerable population with multiple needs. Thus, Sober Network IPT integrates a validated treatment for perinatal MDD with empirically supported SUD principles, using proposed mechanisms that are particularly relevant to the perinatal period and to our target population.

The purposes of this R34 Exploratory Research proposal are to (a) integrate network support strategies for SUD into an IPT framework to create Sober Network IPT for perinatal women with substance use and MDD (b) to collect preliminary data on its feasibility, acceptability, and initial efficacy within a clinical setting in collaboration with community therapists. Attempting to obtain a definitive effect size estimate is not an intended outcome of an R34 given the limited sample sizes typically supportable under this mechanism. The investigators will, however, collect preliminary information to explore potential treatment differences and likely effect size ranges. Findings from this proposal will lay the groundwork for a larger clinical trial.

The development aims of this R34 proposal are to:

  1. Adapt IPT to Sober Network IPT for perinatal women with substance use and MDD.
  2. Develop, implement, and evaluate a therapist training program and competence and adherence scales.
  3. Improve the clarity, content, acceptability, and feasibility of Sober Network IPT using information gathered from two focus groups and a small open trial (n = 6) of perinatal women with substance use and MDD.

The pilot study aims of this R34 proposal are to:

  1. Conduct a randomized pilot trial in a sample of 50 women who meet criteria for substance use and MDD during pregnancy or within one year postpartum to demonstrate the feasibility and acceptability of the proposed recruitment methods and research design, of the therapist training methods, and of delivering the Sober Network IPT treatment.
  2. Examine preliminary evidence for the hypotheses that, relative to treatment-as-usual, Sober Network IPT will result in:

    • Fewer heavy drinking/drug using days through the 3 month follow-up (primary).
    • Reduced depressive symptoms at post-treatment and 3 month follow-up (primary).
    • Improved sober support and social support (secondary).
  3. Explore the feasibility of using fetal, neonatal and infant outcomes and engagement in health prevention activities (such as immunization and well-child visits) as secondary outcomes in a subsequent trial.

As a result of this R34 Exploratory Research Project, the investigators will have adapted IPT into Sober Network IPT, a novel treatment approach for perinatal women with substance use and MDD, tested its feasibility, acceptability, and initial efficacy with an eye toward dissemination (see D2.13), and the investigators will be prepared to test its efficacy in future R01 clinical trials. From a longer term perspective, this program of research will advance clinical care and research endeavors for perinatal women with substance use and MDD; underserved women with clinical concerns that are of great public health significance. Furthermore, if Sober Network IPT is found to be efficacious in our vulnerable target population, the investigators anticipate that it could hold promise for a more heterogeneous substance use and MDD population.

연구 유형

중재적

등록 (실제)

59

단계

  • 1단계

연락처 및 위치

이 섹션에서는 연구를 수행하는 사람들의 연락처 정보와 이 연구가 수행되는 장소에 대한 정보를 제공합니다.

연구 장소

    • Rhode Island
      • Providence, Rhode Island, 미국, 02905
        • Women and Infants Hospital of Rhode Island

참여기준

연구원은 적격성 기준이라는 특정 설명에 맞는 사람을 찾습니다. 이러한 기준의 몇 가지 예는 개인의 일반적인 건강 상태 또는 이전 치료입니다.

자격 기준

공부할 수 있는 나이

18년 (성인)

건강한 자원 봉사자를 받아들입니다

아니

연구 대상 성별

여성

설명

Inclusion Criteria:

  1. pregnant or has delivered in the past year
  2. reports the use of an illegal drug and/or consumption of 4 or more drinks on one occasion within the last 6 months; if postpartum, report the use of an illegal drug and/or consumption of 4 or more drinks on one occasion or 7 or more drinks in a week within the last 6 months; if pregnant, report the use of an illegal drug within the last 6 months and/or the consumption of 2 or more drinks in one month while pregnant, along with a history of consumption of 4 or more drinks on one occasion or 7 or more drinks in a week within 3 months pre-pregnancy
  3. meets DSM-IV criteria of current Major Depressive Disorder (MDD) by Structured Clinical Interview for the DSM-IV(SCID) interview;
  4. has a 17-item Hamilton Rating Scale for Depression (HRSD) score > 16, indicating moderate to severe depression;
  5. is between 18 and 50 years old; and
  6. is able to speak and read English sufficiently to be able to complete the study procedures

Exclusion Criteria:

  1. meets lifetime criteria for:

    • bipolar disorder
    • a primary psychotic disorder
    • anorexia nervosa
    • bulimia nervosa
  2. has started an SUD or MDD medication dose within the 8 weeks prior to enrollment
  3. is imminently suicidal

공부 계획

이 섹션에서는 연구 설계 방법과 연구가 측정하는 내용을 포함하여 연구 계획에 대한 세부 정보를 제공합니다.

연구는 어떻게 설계됩니까?

디자인 세부사항

  • 주 목적: 치료
  • 할당: 무작위
  • 중재 모델: 병렬 할당
  • 마스킹: 하나의

무기와 개입

참가자 그룹 / 팔
개입 / 치료
실험적: Sober Network IPT
Participants are assigned to Sober Network Interpersonal Psychotherapy (IPT)
IPT will be administered in 16 group 90-minute sessions over 18-20 weeks and 3 individual sessions (at the beginning, middle and end of treatment). These sessions will focus on improving your relationships with others, building sober relationships, setting goals, and increasing coping skills.
다른: Treatment as Usual
Participants are assigned to have Treatment as Usual
Women in the treatment as usual condition will either be referred to appropriate treatment in the community or continue their current substance use treatment.

연구는 무엇을 측정합니까?

주요 결과 측정

결과 측정
측정값 설명
기간
Change from baseline in heavy drinking/drug using days at 3 months
기간: up to 3 months post-treatment
Using the Timeline Followback, participants will report their daily use in the time period between each interview (intake, 6 weeks, 12 weeks, 18-20 weeks and 3 months post treatment). The number of heavy drinking/drug using days reported at intake will be compared to the number reported at the followup assessments.
up to 3 months post-treatment
Change from baseline in depressive symptoms at 18-20 weeks
기간: baseline and 18-20 weeks
The total score of the Hamilton Rating Scale for Depression from intake will be compared to the total score at the 18-20 week assessment to show a reduction in the depressive symptoms.
baseline and 18-20 weeks
Change from baseline in depressive symptoms at 3 months
기간: baseline and 3 months post-treatment
The total score of the Hamilton Rating Scale for Depression from intake will be compared to the total score at the 3 month followup assessment to show a reduction in the depressive symptoms.
baseline and 3 months post-treatment

2차 결과 측정

결과 측정
측정값 설명
기간
Change from baseline in Sober and social support at 3 months
기간: up to 3 months post-treatment
Using the total score of the Multidimensional Scale of Perceived Social Support (MSPSS) reported at the intake and at the 3 month followup the improvement in social and sober support will be determined.
up to 3 months post-treatment

공동 작업자 및 조사자

여기에서 이 연구와 관련된 사람과 조직을 찾을 수 있습니다.

수사관

  • 수석 연구원: Caron Zlotnick, PhD, Women and Infants Hospital of Rhode Island

연구 기록 날짜

이 날짜는 ClinicalTrials.gov에 대한 연구 기록 및 요약 결과 제출의 진행 상황을 추적합니다. 연구 기록 및 보고된 결과는 공개 웹사이트에 게시되기 전에 특정 품질 관리 기준을 충족하는지 확인하기 위해 국립 의학 도서관(NLM)에서 검토합니다.

연구 주요 날짜

연구 시작

2011년 7월 1일

기본 완료 (실제)

2015년 12월 1일

연구 완료 (실제)

2015년 12월 1일

연구 등록 날짜

최초 제출

2012년 3월 5일

QC 기준을 충족하는 최초 제출

2012년 3월 9일

처음 게시됨 (추정)

2012년 3월 12일

연구 기록 업데이트

마지막 업데이트 게시됨 (추정)

2016년 3월 30일

QC 기준을 충족하는 마지막 업데이트 제출

2016년 3월 29일

마지막으로 확인됨

2016년 3월 1일

추가 정보

이 연구와 관련된 용어

기타 연구 ID 번호

  • R34DA030428-01A1 (미국 NIH 보조금/계약)

이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .

구독하다